ArticlebioRxiv : the preprint server for biology2024
Advancing Clinical Response Against Glioblastoma: Evaluating SHP1705 CRY2 Activator Efficacy in Preclinical Models and Safety in Phase I Trials.
Priscilla Chan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.